Cardiovascular risk mapping in Netherlands and Australia: a comparative analysis : 2014 APHCRI / Radboudumc International Visiting Fellowship Report by Bagheri, Nasser
 
 
 
 
 
 
 
 
 
Cardiovascular risk mapping 
in the Netherlands and 
Australia: a comparative 
analysis  
2014 APHCRI / Radboudumc 
International Visiting 
Fellowship Report 
 
 
 
 
Nasser Bagheri 
 
December 2015 
P a g e  | 2 
 
A C K N O W L E D G E M E N T S  
 
This research is a project of the Australian Primary Health Care Research Institute, which is 
supported by a grant from the Australian Government Department of Health. The 
information and opinions contained in it do not necessarily reflect the views or policy of the 
Australian Primary Health Care Research Institute or the Australian Government 
Department of Health. 
This research was conducted in collaboration with the Radboudumc in the Department of 
Primary and Health Care, where I was a visiting fellow in April-July 2015. I am grateful for 
the support, guidance, instruction and time invested by the staff and directors both within the 
duration of the fellowship and beyond. 
The following investigators were contributors to the paper which is under preparation, 
Nasser Bagheri1, Paul Konings1, Ian McRae1, Chris van Weel2, Wim de Grauw2, Henk 
Schers2, Tjard Schermer2, Marion Biermans2 
1 Australian National University, School of Population Health 
2 Radboudumc, Department of Primary and health care 
 
 
 
 
 
 
 
 
C I T A T I O N  
Bagheri, N., 2015. Cardiovascular risk mapping in the Netherlands and Australia: a 
comparative analysis. Report on 2015 APHCRI/Radboudumc Visiting Fellowship, Australian 
Primary Health Care Research Institute. Canberra, the Australian Capital Territory. 
 
Dr Nasser Bagheri 
Research School of Population Health 
The Australian National University 
Canberra ACT 2600 Australia 
T   61 2 6125 9564 
F   61 2 6125 7551 
E   Nasser.bagheri@anu.edu.au 
http://www.anu.edu.au/aphcri 
 
  
P a g e  | 3 
CO NT E NT S  
Acronyms .............................................................................................................................. 4 
Fellowship summary ............................................................................................................. 5 
Background ....................................................................................................................... 5 
Methods ................................................................................................................................ 7 
Study areas and data sources ........................................................................................... 7 
Characteristics associated with CVD risk and identifying areas of high risk ....................... 8 
Results ................................................................................................................................ 13 
Further achievements and activities during the International Visiting Fellowship.............. 13 
Discussion .......................................................................................................................... 14 
Conclusion .......................................................................................................................... 15 
Policy recommendations .................................................................................................. 15 
References.......................................................................................................................... 16 
 
 
 
 
 
 
 
  
P a g e  | 4 
 
Acronyms 
ABS  Australian Bureau of Statistics 
BMI  Body Mass Index 
CVD  Cardiovascular Disease 
FRE  Framingham Risk Equation 
GP  General Practitioner 
HDL  Hyper Density Lipoprotein 
IDW  Inverse Distance Weighting 
LVH  Left Ventricular Hypertrophy 
PHC  Primary Health Care 
Radboudumc Radboud University Medical Centre 
SA1  Statistical Area level 1 
SBP  Systolic Blood Pressure 
TC  Total Cholesterol 
CBS                Dutch Central of Bureau of Statistics 
 
  
P a g e  | 5 
Fellowship summary 
Lifestyle-related chronic illnesses (such as diabetes mellitus and cardiovascular disease 
(CVD)) are predicted to rise alarmingly in Australia and worldwide over the next few 
decades, posing challenges that will need to be met by effective preventive medicine 
strategies and primary health care services planning. Chronic disease risk analysis is a key 
area of interest for APHCRI and the Radboudumc Department of Primary and Community 
Care, Nijmegen, The Netherlands. 
The Radboudumc Department of Primary and Community Care is a well-known and active 
research Centre analysing large, longitudinal primary health care and chronic disease data 
in the Netherlands. This visiting fellowship provided a unique opportunity for me to build 
international research relationships and collaborations in primary health care research. It 
also enhanced my international profile as well as that of the National Centre for Geographic 
and Resource Analysis in Primary Health Care (GRAPHC), a spatial modelling service to 
support policy relevant research in primary health care and build research capacity for PHC. 
This opportunity had a great impact on translating evidence-based research findings into the 
development of policy to enable geographic targeting of preventive interventions. The 
APHCRI/ Radboud University Medical Centre visiting fellowship also provided an opportunity 
to access international primary health care data and allowed me to undertake a comparative 
study of geospatial analysis of cardiovascular risk. This was an important opportunity to 
develop my leadership in chronic disease risk mapping and gain further knowledge in the 
area of chronic diseases risk assessment and innovations in primary health care methods. 
The finding could help preventive interventions to be targeted in the right place, at the right 
time, to the right people. It also provides an innovative tool to help address the alarming rise 
of CVD in the Australian and Dutch communities. 
 
BACKGROUND  
CVD is a leading cause of death and disease burden across the world, and the burden is 
expected to increase as the population ages (1–3). CVD is the most expensive disease in 
Australia; it accounted for $7.9 billion, or 11%, of health spending from 2009 to 2010 (1). 
The most commonly used CVD risk prediction algorithms are those derived from the 
Framingham Risk Equation (FRE), which is used in general practice (GP) to assess risks for 
individual patients (4). The trend in primary prevention of CVD in GPs has been to move 
away from assessment of relative CVD risk factors toward assessment and management of 
these factors as absolute CVD risk (5, 6). 
Best-value prevention strategies require knowledge and contextualised understanding of 
people, communities, and environments, as well as variations in CVD risk. Although 
clinically proven tools are available for assessing risk factors in individuals, most at-risk 
individuals never take part in such assessment until disease progression is under way. 
Although imprecise proxies for risk can be used to make community-based risk estimates, 
there is still a considerable knowledge gap; no fine-grained population tools exist to directly 
predict ‘hotspots’ for future CVD risk from GP clinical data. 
Few studies have attempted to examine spatial variation of CVD risk at a smaller geographic 
scale across the world. Noble et al examined the feasibility of mapping chronic disease risk 
in general and created a small-area map of diabetes risk from GP clinical records in the 
United Kingdom (7). In Australia, Tideman et al compared the CVD risk of a population 
survey sample from northwest Adelaide with a nearby rural population but did not look at the 
variation within the survey population catchment area (8). This is the first study that 
visualises the pattern of CVD risk at a small-area scale from GP clinical records to explore 
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possible clusters or hotspots of CVD risk in Dutch and Australian communities. The small 
area used, Statistical Area Level 1 (SA1), has a population size between 200 to 800 people, 
which is approximately equal to the size of a US census block (315 people on average) (9). 
The main objective of this study was to explore patterns of CVD risk in people across small 
areas and investigate the association between area-level socioeconomic and lifestyle status 
and CVD risk patterns in the Netherlands and Australia. This approach allows the production 
of fine-grained maps of CVD risk for use by clinicians and policy makers to enable 
geographic targeting of interventions in communities. 
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Methods 
STUDY AREAS AND DATA SOURCES  
De-identified clinical practice data from 2012 through 2014 were drawn from Adelaide city 
(west) in Australia and Nijmegen City in the Netherlands (see figure 1 and figure 2). The 
data were linked to the four-digit postcodes in the Netherlands (see figure 3) and SA1s in 
Australia (se figure 4) using methods described by Mazumdar et al in 2014 (10). Overall, 
data on 19,000 active patients aged 30 to 74 were extracted from 16 practices in west 
Adelaide. The sample size from GP practices in Nijmegen was 9,000. These actives patients 
had no prior history of CVD (i.e., stroke, chronic heart disease, peripheral vascular disease, 
or heart failure). 
Patients were excluded if data were not available for seven risk factors (Table 1) for CVD, 
which are required to calculate the FRE. A major part of the analysis was based on 
geography, so the patients were classified according to the SA1 in which they resided. To 
maintain confidentiality, the study excluded those SA1s that contained fewer than five 
patients, leaving a sample of 18,835 patients. Under Australian health care, patients access 
primary health care as the point of entry into the health care system, and each year 
approximately 85% of the population has contact with a GP. Therefore, to the degree that 
GPs choose to participate in studies such as these 16 practices, it is possible to obtain high 
patient coverage. 
 
Figure1: the Netherlands and Nijmegen city 
Source: Google online maps, 
https://www.google.com.au/search?q=The+Netherlands+maps&espv=2&biw=1065&bih=707&tbm=isch&imgil=Jjra
9V6Sd7bU6M%253A%253BoVv-
9uw0ivI4aM%253Bhttp%25253A%25252F%25252Fwww.internationalstudents.nl%25252Fmaps-of-the-
netherlands%25252F&source=iu&pf=m&fir=Jjra9V6Sd7bU6M%253A%252CoVv-
9uw0ivI4aM%252C_&usg=__cbaG1dnGgkGtTrWcYSztArNwt8w%3D&ved=0ahUKEwi2sKjhme7JAhUBGqYKHX
ByB_0QyjcIKg&ei=7Jd4VraKFYG0mAXw5J3oDw#imgrc=e_9pgntR2nGyXM%3A&usg=__cbaG1dnGgkGtTrWcY
SztArNwt8w%3D  
 P a g e  | 8 
 
Figure 2: Australia and Adelaide city 
Source: www.freeworldmaps.net  
CHARACTERISTICS ASSO CIATED W ITH CVD 
RISK AND IDENTIFYING  AREAS OF HIGH RISK  
We used the FRE to evaluate 5-year and 10-year absolute risks of CVD for individuals 
based on GP clinical data for the west Adelaide area and Nijmegen city. The FRE, a risk 
model designed for use on individuals’ clinical data, is well-suited for producing population-
level risk estimates (11, 12). The FRE accounts for age, sex, total cholesterol, high-density 
lipoprotein cholesterol, systolic blood pressure, smoking status, and whether a patient has 
diabetes, to estimate the patient’s risk for developing CVD in the next 10 years (see Table 
1). The recommended scoring system has been in use since 1991 (13). We also calculated 
patients’ 5-year risk of CVD using the FRE and compared these data with the 10-year data 
to assess patterns. 
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Table 1: Estimated CVD risk score and corresponding risk factors 
n. Gender Age SBP Smoking TC HDL Diabetes LVH 10Y 
CVD 
risk 
(%) 
1. F 63 139 0 5.7 2.5 0 0 8 
2. M 70 162 0 4.4 1 1 0 48 
3. F 60 151 0 3.5 1.9 1 0 16 
4. M 73 140 0 3.3 1.2 1 0 33 
5. M 71 136 0 4.5 1.71 1 0 29 
6. M 44 150 0 6.2 1.3 0 0 10 
7. M 56 138 1 4.6 1 0 0 28 
8. M 68 153 0 4.8 1.5 0 0 26 
9. F 66 160 1 3.7 2.2 0 0 18 
10. F 55 155 1 7.2 1.5 0 0 25 
 
The National Vascular Disease Prevention Alliance in Australia defined CVD risk category 
on the basis of FRE as follows: an absolute risk of CVD events over 10 years higher than 
20% is high risk; from 10% to 20% is moderate risk, and less than 10% is low risk. Body 
Mass Index (BMI, kg/m2) was not used in the FRE, but because it is a major risk factor for 
CVD we included the distribution of CVD risk by BMI category. We used World Health 
Organization recommendations for BMI cut-offs as follows: underweight, less than 18.5; 
normal weight, 18.5 to 24.9; overweight 25.0 to 29.9; and obese, 30.0 or higher. 
To calculate area/ community level of CVD risk, we first linked the de-identified patient 
records, including calculated absolute 5-year and 10-year CVD risk, to the corresponding 
SA1s and the 4-digit postcodes in west Adelaide and Nijmegen respectively. Second, the 
individual risk scores were aggregated to SA1 and postcode level by calculating mean risk 
for each SA1 and postcode (see Table 2). Third, the area level of CVD risk was visualised to 
examine the areas of high and low probability of developing CVD risk over the next 10 years 
in the study area. 
Table 2: Calculating areas level of CVD risk 
Patient ID Ind. CVD risk SA /postcode ID SA  CVD risk 
10 5% 2011213 6% 
50 10% 2011213 6% 
111 3% 2011213 6% 
30 16% 3001400 12% 
110 8% 3001400 12% 
SA = South Australia 
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An index of relative socioeconomic disadvantage (IRSD) developed by the Australian 
Bureau of Statistics was linked to the corresponding SA1 to make comparisons with the 
pattern of absolute CVD risk (14, 15). IRSD is a general socioeconomic index derived from 
census variables related to disadvantage, such as low income, low educational attainment, 
unemployment, and dwellings without motor vehicles. We ran a linear regression model to 
investigate the relationship between CVD risk and ISRD, adjusting for demographic 
variables. 
 
Figure 3: Geography scale in the Netherlands (left) 
Source: Author adapted using Dutch Central Bureau of Statistics (CBS) 
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Figure 4: The Australian Statistical Geography Standards (ASGS) 2011 structure 
Source: Australian Bureau of Statistics 
 
 
To identify areas with high risk (hotspots) and low risk (coldspots) for CVD, a continuous 
heat map of CVD risk was generated using hotspots analyses. Furthermore, the tertile of the 
index of relative socioeconomic disadvantage was mapped for each SA1 to compare with 
the pattern of CVD risk at the SA1 level in west Adelaide (11). Tertile is any of the two points 
that divide an ordered distribution into three parts, each containing a third of the population. 
However, in the Netherlands we obtained the self-reported lifestyle data at the postcode 
level from the Department of Public Health in Nijmegen to examine their association with 
CVD risk patterns. These lifestyle data include smoking, level of physical activity, vegetable 
consumption, alcohol consumption and financial difficulties. 
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We used Stata version 12.1 (StataCorp, LP) to calculate the CVD risk scores and conduct 
descriptive analyses for our sample population and ArcGIS version 10.2 (Esri) to conduct 
spatial analyses and mapping. The study obtained ethics approval from the Australian 
National University human ethics committee (protocol 2014/174). 
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Results 
A journal paper from the international visiting fellowship is under preparation and detailed 
study results will be available in the publication. Authors will submit the paper to the British 
Medical Journal in the first instance. 
The research finding showed that CVD risk is higher in area with socioeconomic level. 
Additionally people living in neighbourhoods with higher density of public green spaces had 
lower risk of CVD. Figure 3 shows two different neighbourhoods with different CVD risk 
score in that two left hand side photos are representing areas with low CVD risk and two 
right hand side photos indicating areas with high risk.  
 
 
 
Figure 3: Neighbourhood with low CVD risk (two left hand side photos) and high risk (two 
right hand side photos) 
Source: Author 
 
 
FURTHER ACHIEVEMENTS AND ACTIVIT IES 
DURING THE INTERNATIONAL VISIT ING 
FELLOW SHIP 
 Two invited talks at Mashhad University of Medical Science and the Department of 
Khorasan Razavi Public Health, Iran 
 Three presentations at the Radboudumc, the Department of Public Health (GGD) 
and the Department of Primary and Health Care in Nijmegen 
 Two invited talks at the University of Saskatchewan and the Department of Reginal 
Public Health in Saskatoon, Canada. 
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Discussion 
This approach provides an opportunity for researchers who have access to GP-based 
clinical data to further explore prevalence, location, and correlates of CVD and is applicable 
anywhere that these data are available. This method can be used as a tool to identify areas 
of high levels of unmet need for cardiovascular care, which could enable geographic 
targeting of effective interventions for enhancing early and timely detection and 
management of CVD in those communities. Furthermore, this study demonstrates that GP 
data can help identify public health priorities. 
This research aimed to identify area-level CVD risk and the proportion of the population at 
high risk using GP clinical records. Patients’ 5- and 10-year risk scores were generated on 
the basis of the Framingham risk prediction model, and these estimated scores were 
aggregated and visualised at the SA1 level. Finally a ‘heat map’ interpolation surface of 
CVD risk was created to highlight the hotspots (high-risk areas) and coldspots (low-risk 
areas) in the study area. To our knowledge this is the first time area-level CVD risk, 
hotspots, and clustering in CVD risk have been studied using de-identified GP clinical 
records. We found that the proportion of patients at high risk for CVD risk was significantly 
higher in the communities of low socioeconomic status than in those of high socioeconomic 
status. 
A considerable amount of literature has been published on the validity and generalisability of 
the FRE, which has been recommended as the most reliable method of predicting CVD risk 
in the United States (18–20). Many studies have demonstrated that the Framingham method 
of predicting risk is accurate when used on other populations, including most Australians 
and Dutch people (21–23). However, it is not generalisable to every population, and it can 
significantly underestimate the CVD risk of Aborigines (24). The Aboriginal data were poorly 
recorded in our GP dataset, so we were not able to evaluate a CVD risk pattern in Aboriginal 
people. However, the proportion of Aboriginal and Torres Strait Islander people in the 
general population in our study area was approximately 2%. Regardless of its limitations, 
the FRE is recommended by the National Heart Foundation of Australia to calculate CVD 
risk of Australians (25). 
This research addressed a significant public health problem, that of identifying the spatial 
distribution of CVD risk in Australia in a timely way so that prevention services can be more 
efficiently distributed. This project also allows risk profiles to be considered in relation to 
socioeconomic characteristics of areas. Consequently, our approach may be useful in 
describing and exploring spatial inequalities in the distribution of CVD risk, or any chronic 
disease for which risk modelling is available, that contributes to our understanding of health 
inequalities. 
The development of a tool for monitoring disease risk has the potential to improve service 
delivery, policy development, research, and ultimately health outcomes, which would be 
particularly beneficial for people living in underserviced areas. No tools exist in Australia to 
predict risk hotspots in a timely manner, which means that development of chronic disease 
prevention policies at the national, state, and local levels are not informed by the most 
current information about disease risk in specific populations. Additionally, this method 
enables ecological studies of relationship between the area risk and socioeconomic status 
and built environment characteristics such as access to green spaces and fast-food outlets. 
This method can be used to estimate prevalence of CVD risk at different geographical 
scales from GP catchments to the national level, using demographic and clinical risk factors. 
A limitation of this study is that the FRE may underestimate risk for people who take lipid-
lowering or antihypertensive medication or people who have recently stopped smoking (29). 
However, current clinical practice is to calculate people’s risk even if they are taking 
medications (30).
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Conclusion 
This approach provides an opportunity for researchers who have access to GP-based 
clinical data to further explore prevalence, location, and correlates of CVD and is applicable 
anywhere that these data are available. This method can be used as a tool to identify areas 
of high levels of unmet need for cardiovascular care, which could enable geographic 
targeting of effective interventions for enhancing early and timely detection and 
management of CVD in those communities. Furthermore, this study demonstrates that GP 
data can help identify public health priorities. 
 
POLICY RECOMMENDATIO NS 
The research suggested that policy makers could focus on four domains/options in terms of 
CVD risk reduction activities and play a vital role in reducing CVD burden in the 
communities; (1) enhancing GP practice clinical data quality with collaboration of GPs and 
practices and making use of this unique and valuable dataset; (2) individual CVD risk profile 
to identify people with higher risk of CVD in communities; (3) neighbourhood/community 
CVD risk profile to high areas with higher rate of CVD risk, and (4) improve population 
lifestyle in order to mitigate CVD risk and provide high life expectancy for all. 
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